Tuesday, October 18, 2022 9:55:20 AM
October 17 2022 - 05:19PM
GlobeNewswire Inc.
Alert
Share On Facebook
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America’s IDWeek 2022.
The hybrid conference will be held from October 19-23 at the Walter E. Washington Convention Center in Washington, D.C. Posters will be available for registrants on the IDWeek Interactive Program and the IDWeek Mobile App starting on October 19, 8 a.m. ET. Onsite attendees can view posters from Oct. 20-22 from 8 a.m. to 6 p.m.
Data to be presented at IDWeek 2022 include:
Presentation Title: Impact of Asymptomatic Bacteriuria on Primary Efficacy Analyses in the Evaluation of Novel Antimicrobials for the Treatment of Patients with Urinary Tract Infection
Poster #: 227
Presenter: Steven Aronin
Time/Location: Thursday, October 20, 12:15 p.m. - 1:30 p.m. in Hall B+C
Presentation Title: Murine Efficacy Studies of Sulopenem Against Bacillus anthracis
Poster #: 1724
Presenter: Sailaja Puttagunta
Time/Location: Saturday, October 22, 12:15 p.m. - 1:30 p.m. in Hall B+C
These Posters will be made available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab once the conference ends.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
Recent ITRM News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 12:00:08 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/11/2024 08:01:41 PM
- Iterum Therapeutics to Present Data at IDWeek 2024 • GlobeNewswire Inc. • 10/10/2024 12:30:00 PM
- Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit • GlobeNewswire Inc. • 10/09/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/08/2024 01:15:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 09:20:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/30/2024 08:15:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/30/2024 11:30:02 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/24/2024 01:01:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/24/2024 12:59:25 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/23/2024 10:30:01 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/11/2024 08:50:02 PM
- Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/09/2024 10:15:02 AM
- Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference • GlobeNewswire Inc. • 09/06/2024 08:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/14/2024 08:15:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 11:30:26 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:15:36 AM
- Iterum Therapeutics Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/14/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/14/2024 04:15:16 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 08/09/2024 09:28:56 PM
- Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 • GlobeNewswire Inc. • 08/07/2024 08:30:00 PM
- Iterum Therapeutics Announces Expiration and Results of Rights Offering • GlobeNewswire Inc. • 08/06/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 09:25:18 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/02/2024 08:30:02 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM